377 related articles for article (PubMed ID: 34653515)
1. Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts.
Berin MC; Agashe C; Burks AW; Chiang D; Davidson WF; Dawson P; Grishin A; Henning AK; Jones SM; Kim EH; Leung DYM; Masilamani M; Scurlock AM; Sicherer SH; Wood RA; Sampson HA
J Allergy Clin Immunol; 2022 Apr; 149(4):1373-1382.e12. PubMed ID: 34653515
[TBL] [Abstract][Full Text] [Related]
2. Allergen-specific oral immunotherapy for peanut allergy.
Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
[TBL] [Abstract][Full Text] [Related]
4. The effect of oral immunotherapy treatment in severe IgE mediated milk, peanut, and egg allergy in adults.
Mäntylä J; Thomander T; Hakulinen A; Kukkonen K; Palosuo K; Voutilainen H; Pelkonen A; Kauppi P
Immun Inflamm Dis; 2018 Jun; 6(2):307-311. PubMed ID: 29542268
[TBL] [Abstract][Full Text] [Related]
5. Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.
Bajzik V; DeBerg HA; Garabatos N; Rust BJ; Obrien KK; Nguyen QA; O'Rourke C; Smith A; Walker AH; Quinn C; Gersuk VH; Farrington M; Jeong D; Vickery BP; Adelman DC; Wambre E
Allergy; 2022 Aug; 77(8):2534-2548. PubMed ID: 35266148
[TBL] [Abstract][Full Text] [Related]
6. Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children.
Thyagarajan A; Jones SM; Calatroni A; Pons L; Kulis M; Woo CS; Kamalakannan M; Vickery BP; Scurlock AM; Wesley Burks A; Shreffler WG
Clin Exp Allergy; 2012 Aug; 42(8):1197-205. PubMed ID: 22805467
[TBL] [Abstract][Full Text] [Related]
7. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.
Kim EH; Yang L; Ye P; Guo R; Li Q; Kulis MD; Burks AW
J Allergy Clin Immunol; 2019 Nov; 144(5):1320-1326.e1. PubMed ID: 31493887
[TBL] [Abstract][Full Text] [Related]
8. Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy.
Sicherer SH; Wood RA; Stablein D; Burks AW; Liu AH; Jones SM; Fleischer DM; Leung DY; Grishin A; Mayer L; Shreffler W; Lindblad R; Sampson HA
J Allergy Clin Immunol; 2010 May; 125(5):1077-1083.e8. PubMed ID: 20451041
[TBL] [Abstract][Full Text] [Related]
9. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
[TBL] [Abstract][Full Text] [Related]
10. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).
Syed A; Garcia MA; Lyu SC; Bucayu R; Kohli A; Ishida S; Berglund JP; Tsai M; Maecker H; O'Riordan G; Galli SJ; Nadeau KC
J Allergy Clin Immunol; 2014 Feb; 133(2):500-10. PubMed ID: 24636474
[TBL] [Abstract][Full Text] [Related]
11. Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis.
de Silva D; Rodríguez Del Río P; de Jong NW; Khaleva E; Singh C; Nowak-Wegrzyn A; Muraro A; Begin P; Pajno G; Fiocchi A; Sanchez A; Jones C; Nilsson C; Bindslev-Jensen C; Wong G; Sampson H; Beyer K; Marchisotto MJ; Fernandez Rivas M; Meyer R; Lau S; Nurmatov U; Roberts G;
Allergy; 2022 Jun; 77(6):1852-1862. PubMed ID: 35001400
[TBL] [Abstract][Full Text] [Related]
12. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults.
Jones SM; Sicherer SH; Burks AW; Leung DY; Lindblad RW; Dawson P; Henning AK; Berin MC; Chiang D; Vickery BP; Pesek RD; Cho CB; Davidson WF; Plaut M; Sampson HA; Wood RA;
J Allergy Clin Immunol; 2017 Apr; 139(4):1242-1252.e9. PubMed ID: 28091362
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
[TBL] [Abstract][Full Text] [Related]
14. The Consortium for Food Allergy Research (CoFAR): The first generation.
Sampson HA; Berin MC; Plaut M; Sicherer SH; Jones S; Burks AW; Lindblad R; Leung DYM; Wood RA
J Allergy Clin Immunol; 2019 Feb; 143(2):486-493. PubMed ID: 30586557
[TBL] [Abstract][Full Text] [Related]
15. Skin prick test responses and allergen-specific IgE levels as predictors of peanut, egg, and sesame allergy in infants.
Peters RL; Allen KJ; Dharmage SC; Tang ML; Koplin JJ; Ponsonby AL; Lowe AJ; Hill D; Gurrin LC;
J Allergy Clin Immunol; 2013 Oct; 132(4):874-80. PubMed ID: 23891354
[TBL] [Abstract][Full Text] [Related]
16. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.
Fleischer DM; Greenhawt M; Sussman G; Bégin P; Nowak-Wegrzyn A; Petroni D; Beyer K; Brown-Whitehorn T; Hebert J; Hourihane JO; Campbell DE; Leonard S; Chinthrajah RS; Pongracic JA; Jones SM; Lange L; Chong H; Green TD; Wood R; Cheema A; Prescott SL; Smith P; Yang W; Chan ES; Byrne A; Assa'ad A; Bird JA; Kim EH; Schneider L; Davis CM; Lanser BJ; Lambert R; Shreffler W
JAMA; 2019 Mar; 321(10):946-955. PubMed ID: 30794314
[TBL] [Abstract][Full Text] [Related]
17. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
[TBL] [Abstract][Full Text] [Related]
18. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
[TBL] [Abstract][Full Text] [Related]
19. Suppression of the immunologic response to peanut during immunotherapy is often transient.
Gorelik M; Narisety SD; Guerrerio AL; Chichester KL; Keet CA; Bieneman AP; Hamilton RG; Wood RA; Schroeder JT; Frischmeyer-Guerrerio PA
J Allergy Clin Immunol; 2015 May; 135(5):1283-92. PubMed ID: 25542883
[TBL] [Abstract][Full Text] [Related]
20. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.
Kim EH; Keet CA; Virkud YV; Chin S; Ye P; Penumarti A; Smeekens J; Guo R; Yue X; Li Q; Kosorok MR; Kulis MD; Burks AW
J Allergy Clin Immunol; 2023 Jun; 151(6):1558-1565.e6. PubMed ID: 36828080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
